NasdaqGM:CSTLHealthcare
Castle Biosciences (CSTL) Q4 EPS Loss Tests Bullish Profitability Narrative
Castle Biosciences (CSTL) has wrapped up FY 2025 with Q4 revenue of US$87 million and a basic EPS loss of US$0.08, alongside trailing twelve month revenue of US$344.2 million and a basic EPS loss of US$0.83. Over recent periods, the company has seen quarterly revenue range from US$83 million to US$88 million, while basic EPS has moved between a loss of US$0.90 and a profit of US$0.16. This sets the stage for investors to focus closely on how those revenue levels translate into sustainable...